We are proud to announce a significant milestone for Cizzle Bio, Inc. The CIZ1B biomarker test, developed by Cizzle Biotechnology Holdings PLC, has been selected for a crucial clinical study at a premier US cancer center. This selection underscores the test’s potential to transform early lung cancer detection.
Key Highlights:
- Study Role: The CIZ1B test is set to validate lung nodules detected by CT scans, enhancing diagnostic accuracy.
- Strategic Licensing: Cizzle Bio, Inc. holds the exclusive North American rights to develop and market this promising technology.
- Financial Milestones: The collaboration will generate milestone payments and royalties for Cizzle Biotechnology, securing a sustainable financial future.
- Future Developments: With the clinical lab registration expected by this September and a full product launch by April 2025, we are on the brink of revolutionizing lung cancer diagnostics.
For more in-depth details on this exciting development, visit Cizzle Bio’s website.